Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Site Payment Paradigm Shift: Using Electronic Data Capture To Replace Excel



At a recent meeting at the Pharmaceutical Contract Management Group about site payments, pharma sponsors and clinical research organizations (CROs) outlined the complicated and manual process of paying clinical trial sites.

Share this!

November 22, 2016 | by Marcus Thornton, Principal, Platform Adoption, Medidata

Medidata Solutions has done research that suggests up to 40 percent of a clinical trial budget is devoted to investigator payments; this is a significant piece of the financial consideration for a life science company. So can the process payment be improved?

At a recent meeting at the Pharmaceutical Contract Management Group about site payments, pharma sponsors and clinical research organizations (CROs) outlined the complicated and manual process of paying clinical trial sites.

We have heard from countless sponsors and CROs about the difficulties they face when trying to maintain timely payments to clinical trial sites scattered around the globe. There are difficulties with reporting, indirect tax considerations that vary country by country and a multitude of other global complexities.

The reality is that a lot of the industry still handles payments manually through Excel spreadsheets combined with enterprise resource planning (ERP) software. This pieced-together solution often results in late and inaccurate payments to sites.

Excel is a fine program, but it and similar software weren’t developed specifically with the payment process in mind. They require users to dig through spreadsheets and create workarounds to execute payments. Without payment technology, processing payments can be a time consuming and error prone process, and it can be difficult to track accruals which is needed to manage cash flow.

We estimate that roughly 40 percent of new sites that participate in a trial drop out after their first study, citing late payments as one of the key factors. So what does this mean for life science companies that are expanding into new regions, expanding the size of their trials, etc.?

Throughout the industry, pharma companies are bringing payment technology in-house, similar to what happened with electronic data capture (EDC), which can centralize the process for CROs and give sponsors the insight they need.

Interestingly, life science companies and CROs have an opportunity to drive site behavior by linking EDC to their payments process, which can improve the site experience through timely, accurate payments, while also encouraging sites to enter data faster.

At the end of November, we are organizing a webinar with Victoria Moore, executive director of global business finance at INC Research and Shaun Williams, director of investigator payments, also of INC Research. They will walk through their experience transitioning a large pharma company from a custom in-house developed tool to turnkey technology for their payment processes.

If you’re still using Excel to manage site payments, this webinar will discuss alternatives to streamline the process. I am certain you will walk away with a new outlook on site payments.

Keywords: Site Payment, Clinical Trials, Electronic Data Capture



        Share this with your colleagues!

        Will Pharmaceutical Serialization Solve All of Our Drug Counterfeiting Problems?

        March 22, 2017 - In response to the growing threat posed by drug counterfeiting, international regulators have begun implementing guidelines aimed at increasing control over the pharmaceutical supply chain. Will these efforts be enough?

        The Future of Real-World Evidence

        March 14, 2017 - Life Sciences companies are performing advanced analytics, including cohort and predictive analytics, on top of these Real-World Evidence (RWE) data sources to understand the performance of their drugs and devices when used by actual, non-clinical trials patients.

        Pharmaceutical Industry Cannibalization: The Launch of Authorized Generics After the Loss of Market Exclusivity

        March 7, 2017 - Once a drug begins to reach the end of its patent period, it’s vulnerable to being scooped up by generic drugmakers who seek to develop a copycat version of the medication. Authorized generics are identical to the company’s branded product in terms of both active and inactive excipient ingredients; the only thing missing is the brand name and packaging that comes along with it.


        Top Ten Webinar Production Tips of 2016


        Strategies for Deploying Innovative Solutions for Perimeter Security

        Natural History vs. Registry Studies in Rare Disease

        The FDA Guidance on the Assessment of Abuse Potential of Drug – A Critical Review

        Combination Product Regulatory Requirement Complexities and the Impact of the 21st Century Cures Act

        Copyright © 2016-2017 Honeycomb Worldwide Inc.